Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anacetrapib Efficacy and Tolerability Study
NCT01717300Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2012
- Primary completion
- Oct 2014
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of anacetrapib in hypercholesterolemia, hypoalphalipoproteinemia, sponsored by Merck & Co.. Started Nov 2012; status: completed.
02
Drugs
anacetrapib
03
Conditions
hypercholesterolemiahypoalphalipoproteinemia
Beyond the preview
Go deeper on NCT01717300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01717300.